tedalinab

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = (4S,7R)-1-(2,4-difluorophenyl)-N-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-4,7-methano-1H-indazole-3-carboxamide

| image = Tedalinab.svg

| image_class = skin-invert-image

| width = 200

| tradename =

| legal_status =

| routes_of_administration =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 916591-01-0

| PubChem = 24872953

| ChemSpiderID = 29340966

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 5R7X34Y6Q1

| C=19 | H=21 | F=2 | N=3 | O=1

| smiles = CC(C)(C)NC(=O)C1=NN(C2=C1[C@@H]3CC[C@H]2C3)C4=C(C=C(C=C4)F)F

| StdInChI = 1S/C19H21F2N3O/c1-19(2,3)22-18(25)16-15-10-4-5-11(8-10)17(15)24(23-16)14-7-6-12(20)9-13(14)21/h6-7,9-11H,4-5,8H2,1-3H3,(H,22,25)/t10-,11+/m0/s1

| StdInChIKey = NTPZXHMTJGOMCJ-WDEREUQCSA-N

}}

Tedalinab (GRC-10693) is a drug developed by Glenmark Pharmaceuticals for the treatment of osteoarthritis and neuropathic pain, which acts as a potent and selective cannabinoid CB₂ receptor agonist. It has a very high selectivity of 4700x for CB₂ over the related CB₁ receptor, has good oral bioavailability and has shown promising safety results and effective analgesic and antiinflammatory actions in early clinical trials.[http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=183092 Glenmark’s Molecule for Neuropathic Pain, Osteoarthritis - GRC 10693, Successfully Completes Phase I Trials. April 13, 2009.] Many related compounds are known, most of which also show high CB₂ selectivity.[http://www.wipo.int/patentscope/search/en/WO2006129178 Glenmark Pharmaceuticals. NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION, Filed June 1st, 2006. WO 2006/129178.]